ZOLTAN KISS CONSULTING

A Family Company

Zoltan Kiss Consulting (ZKC) is a start-up family-owned biotechnological company which discovered in a suitable animal model of pancreatitis that a non-toxic human protein (ZKPr1) normalizes related type 3c diabetes. In in vitro experiments ZKPr1 protected human islet beta cells against agents that exert harmful effects on these cells. Based on these findings, one of the immediate goals of the company is to clarify if such a mechanism also explains the antidiabetic effect of this drug candidate in vivo under the condition of various forms of experimental pancreatitis in mice.

Diabetes mellitus secondary to chronic pancreatitis (diabetes 3c) appears to have a prevalence of around 7% among all diabetics (N. Ewald, C. Kaufmann, A. Raspe, H. U. Kloer, R. G. Bretzel, and P. D. Hardt, Diabetes Metab Res Rev, 28, 338-342, 2012). Due to the complex pathophysiology of type 3c diabetes mellitus, its clinical and laboratory features are very distinct from both type 1 and type 2 diabetes, and for that reason it is not always classified as such. However, there is no specific treatment for type 3c diabetes other than those used to type 2 diabetes including insulin. The company’s goal is to develop ZKPr1, with the help of a financially stronger partner company or companies, for the treatment of type 3c diabetes in humans.

ZKPr1 is available in recombinant form. It is produced from tobacco leaves at 98% purity.